http://www.dailypolitical.com/2016/10/08/sigma-planning-corp-acquires-2704-shares-of-merck-co-mrk.html
http://www.dailypolitical.com/2016/10/08/los-angeles-capital-management-equity-research-inc-has-142039000-position-in-merck-co-mrk.html

http://www.finanznachrichten.de/nachrichten-2016-10/38801457-merck-announces-longer-term-follow-up-of-overall-survival-data-for-keytruda-pembrolizumab-in-patients-with-advanced-melanoma-from-keynote-002-presen-004.htm
http://www.4-traders.com//MERCK-CO-INC-13611/news/Merck-Announces-Longer-Term-Follow-Up-of-Overall-Survival-Data-for-KEYTRUDA-pembrolizumab-in-Pa-23184265/

http://www.marketwatch.com/story/new-keytruda-pembrolizumab-data-in-advanced-urothelial-cancer-demonstrate-overall-response-rate-of-24-percent-in-cisplatin-ineligible-patients-2016-10-08
http://www.4-traders.com//MERCK-CO-INC-13611/news/Merck-New-KEYTRUDA-pembrolizumab-Data-in-Advanced-Urothelial-Cancer-Demonstrate-Overall-Respons-23183896/
http://www.marketwatch.com/story/merck-animal-health-announces-usda-approval-of-innovative-canine-flu-bivalent-vaccine-2016-10-07

http://www.cnbc.com/2016/10/07/bristol-myers-mercks-lung-cancer-treatments-square-off-this-weekend.html
http://manufacturing.pharmaceutical-business-review.com/news/merck-opens-biopharmaceutical-support-center-in-korea-071016-5027167
http://www.dailypolitical.com/2016/10/06/paragon-capital-management-ltd-continues-to-hold-stake-in-merck-co-mrk.html
http://www.dailypolitical.com/2016/10/06/merck-co-mrk-shares-sold-by-security-national-trust-co.html
http://www.investors.com/news/technology/biomarin-incyte-kite-get-thumbs-up-on-goldman-sachs-upgrade/
http://investorplace.com/2016/10/10-pharmaceuticals-stocks-to-buy-now-2/
http://www.marketwatch.com/story/additional-phase-1-data-from-echo-202-reinforce-durability-of-response-in-patients-with-treatment-naive-advanced-or-metastatic-melanoma-treated-with-epacadostat-in-combination-with-keytruda-pembrolizumab-2016-10-07

http://www.4-traders.com//INCYTE-CORPORATION-9675/news/Incyte-Additional-Phase-1-Data-from-ECHO-202-Reinforce-Durability-of-Response-in-Patients-with-Tre-23179400/
http://www.dailymail.co.uk/~/article-3828484/index.html
http://www.wgmd.com/better-buy-exelixis-inc-vs-roche/
http://www.fool.com/investing/2016/10/08/better-buy-exelixis-inc-vs-roche.aspx?source=eptfxblnk0000004&utm_campaign=article&utm_medium=feed&utm_source=foxbusiness
http://www.fool.com/investing/2016/10/08/better-buy-exelixis-inc-vs-roche.aspx
http://www.emailwire.com/release/281938-Glaucoma-Treatment-Market-Trends-Opportunities-And-Analysis.html
http://irishamerica.com/2016/10/irish-america-celebrates-3rd-annual-healthcare-life-sciences-50/
http://arstechnica.com/science/2016/10/for-ripping-off-medicaid-epipen-maker-mylan-pays-feds-465-million/
http://www.eastbaytimes.com/2016/10/07/ad-watch-will-proposition-61-hurt-veterans/
http://www.benzinga.com/general/biotech/16/10/8535229/exclusive-interview-with-delmar-pharmaceutical-ceo-jeffrey-bacha
http://www.emailwire.com/release/281932-MO-Source-Industry-Professional-Survey-Growth-Size-Shares-Forecast-Analysis-and-Supply-Demand-to-2021.html
http://www.emailwire.com/release/281608-Worldwide-Pneumococcal-Vaccine-Market-2016-Trend-Analysis-and-Overview.html
http://www.sun-sentinel.com/business/careers/fl-challenger-job-cuts-september-20161007-story.html
money.aol.co.uk/2016/10/07/should-you-buy-these-two-big-fallers-today/
http://media.wben.com/a/116993298/bills-sunday-preview-with-murph-mark.htm
http://www.emailwire.com/release/281610-Worldwide-Biosimilars-Market-2016-Trend-Analysis-and-Overview.html

http://www.prnewswire.co.uk/news-releases/pre-eclampsia-pipeline---market-analysis-therapeutics-under-development-h2-2016-596285541.html
http://www.sheridansun.com/just-as-you-suspected-all-along-firing-middle-managers-is-good-for-business/
